• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Nitric Oxide Inhibition Partially Normalizes Cortical Proteins in Autism Mouse Models

by
November 20, 2026
in Biology
Reading Time: 6 mins read
0
Nitric Oxide Inhibition Partially Normalizes Cortical Proteins in Autism Mouse Models

Nitric Oxide Inhibition Partially Normalizes Cortical Proteins in Autism Mouse Models

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Pharmacological inhibition of neuronal nitric oxide synthase partially restored cortical protein alterations and ameliorated autism-like behaviors across two distinct mouse models of autism spectrum disorder, according to research published in Molecular Autism. Investigating male mice carrying mutations in either the contactin-associated protein-like 2 gene or the SH3 and multiple ankyrin repeat domains 3 gene, researchers evaluated how targeted suppression of nitric oxide production influences wide-scale proteomic networks in the brain cortex. Autism spectrum disorder is a highly heritable and heterogeneous neurodevelopmental condition characterized by deficits in social communication, repetitive behaviors, and restricted interests. Over a thousand risk genes have been linked to the condition, yet the biological pathways that converge downstream of disparate genetic lesions remain incompletely mapped. The study demonstrated that despite having fundamentally distinct genetic mutations affecting either presynaptic or postsynaptic machinery, both mutant strains shared widespread disruptions in synaptic, neurodevelopmental, and metabolic cortical proteins that were partially reversed following treatment with the inhibitor 7-Nitroindazole.

The two genetic lines examined in the investigation represent established preclinical systems for probing autism spectrum disorder biology. The CNTNAP2 gene encodes CASPR2, a presynaptic transmembrane protein that participates in neuronal migration, myelination, and neurotransmission across both inhibitory gamma-aminobutyric acid systems and excitatory glutamatergic circuits. Conversely, the SHANK3 gene encodes a postsynaptic density scaffolding protein localized to excitatory synapses that orchestrates synapse formation, structural maturation, synaptic development, and maintenance, with SHANK3 disruptions present in more than one percent of clinical autism cases. In prior investigations, both Cntnap2-null and Shank3-mutant mice displayed parallel behavioral impairments, including reduced sociability, deficits in social novelty preference, decreased novelty-seeking behavior, elevated anxiety, and repetitive actions, alongside documented abnormalities in synaptic protein expression and dendritic spine density. Those earlier experiments implicated dysregulated nitric oxide signaling and nitric oxide-mediated post-translational modifications, particularly S-nitrosylation, as key pathological drivers.

Nitric oxide operates physiologically as a diffusible gaseous radical acting as both an intracellular second messenger and an unconventional neurotransmitter synthesized from L-arginine by nitric oxide synthase enzymes. While physiological concentrations regulate vascular tone, neurodevelopment, and synaptic plasticity, excessive nitrosative stress can disrupt essential protein function, mitochondrial respiration, and neurogenesis. To mitigate excess nitric oxide generation in the brain, the researchers administered 7-Nitroindazole, a relatively selective, lipophilic neuronal nitric oxide synthase inhibitor that readily crosses the blood-brain barrier via passive diffusion by competing directly with L-arginine. The experimental protocol enrolled six-week-old male homozygous Cntnap2 knockout mice alongside C57BL/6J wild-type control mice, together with six-week-old homozygous Shank3 mutant mice paired with their respective wild-type littermate controls. Animals received daily intraperitoneal injections of 7-Nitroindazole at a dosage of 80 milligrams per kilogram dissolved in dimethyl sulfoxide and corn oil, or received the vehicle solution alone, over a continuous duration of ten consecutive days.

Behavioral profiles were reanalyzed across six distinct experimental cohorts comprising wild-type controls, untreated mutants, and 7-Nitroindazole-treated mutants for each genetic background using a representative sample of ten mice per group. Automated tracking conducted with EthoVision XT 16 captured behavioral measurements beginning on the fourth day of pharmacological intervention. In open field locomotor assays assessing movement velocity across a five-minute trial, neither mutant strain exhibited altered baseline locomotion compared with wild-type counterparts, nor did 7-Nitroindazole alter velocity. However, in novel object recognition trials assessing recognition memory, wild-type animals spent significantly more time exploring an unfamiliar object, whereas untreated mutants in both cohorts exhibited no preference between familiar and novel objects. Systemic 7-Nitroindazole treatment restored novel object exploration preference in both Cntnap2 and Shank3 mutants. In elevated plus maze tests evaluating anxiety-like behavior, untreated mutant animals spent markedly less time exploring the open arms relative to wild-type controls, whereas ten days of 7-Nitroindazole administration significantly elevated open-arm exploration time back toward wild-type levels in both genetic models.

Social interaction assessments conducted across the three-chamber paradigm further clarified the functional behavioral consequences of neuronal nitric oxide synthase inhibition. During initial sociability testing, wild-type mice exhibited strong preferences for spending time in the chamber containing an unfamiliar conspecific mouse over an empty enclosure, a preference that was absent in both untreated Cntnap2 and Shank3 mutants. Treatment with 7-Nitroindazole restored sociability preferences toward normal wild-type baselines in both mouse strains. In contrast, evaluations of social novelty preference revealed divergent responses between the two strains. When presented with a choice between a familiar cage companion and a novel stranger mouse, untreated mutants in both lines failed to demonstrate the typical wild-type preference for the novel animal. Following 7-Nitroindazole administration, this social novelty impairment was successfully rescued in Shank3 mutants, whereas Cntnap2 mutants showed no significant behavioral recovery on the social novelty metric, underscoring that certain behavioral dimensions retain model-specific resistance to intervention.

To uncover the molecular substrates associated with these phenotypes, the authors performed mass spectrometry-based global proteomic profiling on cortical tissue harvested from both cohorts under baseline conditions and following 7-Nitroindazole treatment. Cortical lysates, analyzed with four biological replicates per group in the Cntnap2 cohort and three biological replicates per group in the Shank3 cohort, underwent protein extraction, reduction, alkylation, and trypsin digestion on S-Trap minicolumns prior to split-less nano-ultra performance liquid chromatography and high-resolution tandem mass spectrometry on Q Exactive HFX or Fusion Lumos instruments. Proteomic quantification identified 4,823 total cortical proteins in Cntnap2 mice, among which 608 were classified as differentially expressed proteins relative to wild-type controls. In Shank3 cortical tissues, 8,754 proteins were detected, of which 512 fulfilled differential expression criteria. Bioinformatics mapping based on mammalian phenotype ontologies revealed prominent enrichment of abnormal behavior categories in both models, encompassing 223 differentially expressed proteins in Cntnap2 mice and 173 differentially expressed proteins in Shank3 mice, alongside categories spanning anxiety, novelty responses, and synaptic signaling.

Comparative systems biology analyses revealed substantial molecular convergence between the two autism mouse models despite their opposing presynaptic and postsynaptic genetic etiologies. Direct comparison established that 73 differentially expressed proteins were shared identically between the Cntnap2 and Shank3 baseline cortical profiles, representing approximately 14.26 percent of all altered proteins identified in Shank3 mutants and yielding a Jaccard overlap index of 6.98 percent. Ontological enrichment of these shared proteins revealed clustering within synapses, glutamatergic transmission pathways, and cellular metabolic machinery, with a subset mapping to oxidative phosphorylation complexes I, III, and IV. Across broader pathway categories, the two strains shared 65 mammalian phenotypes, 133 cellular components, 131 biological processes, and 78 functional signaling pathways, including excitation-inhibition balance networks, dendritic spine organization, and messenger RNA processing. Alongside these shared properties, model-specific signatures emerged: Cntnap2 cortices exhibited unique enrichments in motor phenotypes, aminoacyl-tRNA components, and serotonergic pathways, while Shank3 cortices exhibited distinct enrichments in sensorimotor startle responses and ion homeostasis processes.

Pharmacological treatment with 7-Nitroindazole dramatically reshaped the cortical proteomic landscape, identifying 905 differentially expressed proteins in treated Cntnap2 mice and 616 in treated Shank3 mice relative to untreated mutant baselines, with 98 altered proteins shared across both cohorts. When evaluating restoration toward normal wild-type expression levels, 367 of the 608 baseline protein alterations in Cntnap2 mutants and 445 of the 512 baseline alterations in Shank3 mutants were no longer significantly different from wild-type levels following 7-Nitroindazole administration. Cross-referencing against high-confidence human autism risk genes documented in the Simons Foundation Autism Research Initiative database identified substantial overlap: 80 differentially expressed proteins in baseline Cntnap2 mice, 67 in baseline Shank3 mice, 107 in treated Cntnap2 mice, and 68 in treated Shank3 mice were encoded by established high-risk genes possessing over 90 percent sequence conservation with human orthologs, including PTEN, CDH10, SCN2A, MECP2, and SYNCRIP.

Domain-specific bioinformatics demonstrated that partially rescued proteins clustered within behavior, dendritic spine structure, and excitation-inhibition neurotransmission. In Shank3 cortices, normalized proteins included metabotropic glutamate receptor 3, gamma-aminobutyric acid type A receptor beta 2 subunit, astrocytic excitatory amino acid transporter 2, neurogranin, and tropomyosin receptor kinase B, while Cntnap2 cortices exhibited recovery of voltage-gated potassium channel Kv1.2, AMPA receptor subunit GluA3, dynamin-1, and leucine-rich repeat LGI family member 3. Dendritic spine-related proteins restored by treatment included the P/Q-type calcium channel CaV2.1 and scaffolding protein CASK in Cntnap2 mice, alongside synaptic vesicle regulators SV2A, synaptophysin, and glutaminase in Shank3 mutants. Orthogonal western blotting on cortical lysates evaluating GluA3, GABRB2, and TrkB demonstrated directional agreement with the mass spectrometry fold-change measurements across both models, although the western blot differences did not reach independent statistical significance.

The study authors highlighted several methodological limitations that temper broader clinical interpretations. Proteomic profiling was strictly restricted to cortical tissue, leaving potential regional variations across the striatum, hippocampus, and amygdala unexplored. Furthermore, while liquid chromatography-mass spectrometry provides broad proteome coverage, the technique may have reduced sensitivity for low-abundance proteins, and the small tissue cohort sizes of three to four animals per arm suggest that larger experimental cohorts will be needed to enhance statistical power. Finally, the authors noted that while 7-Nitroindazole serves as a widely utilized inhibitor, potential off-target pharmacological effects must be considered, warranting future validation using genetic knockout models or highly selective alternative compounds. Nevertheless, the identified proteomic shifts demonstrate that excess nitric oxide represents a shared downstream pathological mechanism in genetically diverse forms of autism, supporting further preclinical investigation of nitric oxide synthase modulation.

Subject of Research: Cortical proteomic remodeling and behavioral effects of neuronal nitric oxide synthase inhibition in autism mouse models

Article Title: Nitric oxide inhibition ameliorates cortical proteomic changes in the Cntnap2-/- and Shank3Δ4–22 mouse models of autism spectrum disorder

Article References: Bazbaz, W., Kartawy, M., Khaliulin, I., & Amal, H. (2026). Nitric oxide inhibition ameliorates cortical proteomic changes in the Cntnap2-/- and Shank3Δ4–22 mouse models of autism spectrum disorder. Molecular Autism, 17(1), Article 21. https://doi.org/10.1186/s13229-026-00716-1

Image Credits: AI Generated

DOI: 10.1186/s13229-026-00716-1

Keywords: autism spectrum disorder, nitric oxide, neuronal nitric oxide synthase, 7-Nitroindazole, Cntnap2, Shank3, cortical proteomics, mass spectrometry, synaptic transmission, dendritic spines, excitation-inhibition balance, SFARI risk genes, GluA3, GABRB2, TrkB, behavioral neuroscience, systems biology, neurodevelopment

News Source: Drew Townsend. (November 20, 2026). Nitric Oxide Inhibition Partially Normalizes Cortical Proteins in Autism Mouse Models. Scienmag.

Tags: 7-Nitroindazoleautism spectrum disorderbehavioral neuroscienceCNTNAP2cortical proteomicsdendritic spinesexcitation-inhibition balanceGABRB2GluA3mass spectrometryneurodevelopmentneuronal nitric oxide synthasenitric oxideSFARI risk genesSHANK3synaptic transmissionsystems biologyTrkB
Share12Tweet7Share2ShareShareShare1

Related Posts

Dual Therapy Reduces Brain Membrane Thickening in Infant With Rare Nevus Syndrome

Dual Therapy Reduces Brain Membrane Thickening in Infant With Rare Nevus Syndrome

November 20, 2026
Raising Bioreactor pH Optimizes Bacterial Bioplastic Production From Volatile Fatty Acids

Raising Bioreactor pH Optimizes Bacterial Bioplastic Production From Volatile Fatty Acids

November 20, 2026

Gestational Breast Cancer Exhibits Distinct Molecular Signatures and Lower Immune Infiltration

November 20, 2026

Cranial Suture Stem Cells and Artificial Intelligence Point Toward Biological Craniosynostosis Therapies

November 20, 2026

POPULAR NEWS

  • Targeting Folate Receptor Overcomes Immunotherapy Resistance in Colorectal Cancer in Mice

    Targeting Folate Receptor Overcomes Immunotherapy Resistance in Colorectal Cancer in Mice

    29 shares
    Share 12 Tweet 7
  • Jiangxi Cities Narrowed Gaps in Healthcare Workforce and Beds Over Ten Years

    29 shares
    Share 12 Tweet 7
  • Dimethoate Metabolites Pose Greater Predicted Toxicological Risks Than Parent Insecticide

    29 shares
    Share 12 Tweet 7
  • Dual-Frequency Electroacupuncture Modulates Neurotransmitters and Relieves Insomnia in Mice

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dual Therapy Reduces Brain Membrane Thickening in Infant With Rare Nevus Syndrome

Twenty-Eight Percent of Postpartum Women in Northwest Ethiopia Experience Urinary Incontinence

Cochlear Implants Improve Hearing in Rare MELAS Syndrome Despite Perioperative Challenges

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.